NO20013271L - Fremgangsmate for separering av virale partikler - Google Patents

Fremgangsmate for separering av virale partikler

Info

Publication number
NO20013271L
NO20013271L NO20013271A NO20013271A NO20013271L NO 20013271 L NO20013271 L NO 20013271L NO 20013271 A NO20013271 A NO 20013271A NO 20013271 A NO20013271 A NO 20013271A NO 20013271 L NO20013271 L NO 20013271L
Authority
NO
Norway
Prior art keywords
viral particles
separating viral
quantification
purification
separating
Prior art date
Application number
NO20013271A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013271D0 (no
Inventor
Francis Blanche
Anne Barbot
Beatrice Cameron
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9816737A external-priority patent/FR2788064B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20013271D0 publication Critical patent/NO20013271D0/no
Publication of NO20013271L publication Critical patent/NO20013271L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20013271A 1998-12-31 2001-06-29 Fremgangsmate for separering av virale partikler NO20013271L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9816737A FR2788064B1 (fr) 1998-12-31 1998-12-31 Methode de separation de particules virales
US11994899P 1999-02-12 1999-02-12
PCT/FR1999/003315 WO2000040702A1 (fr) 1998-12-31 1999-12-30 Methode de separation de particules virales

Publications (2)

Publication Number Publication Date
NO20013271D0 NO20013271D0 (no) 2001-06-29
NO20013271L true NO20013271L (no) 2001-08-28

Family

ID=26234748

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013271A NO20013271L (no) 1998-12-31 2001-06-29 Fremgangsmate for separering av virale partikler

Country Status (15)

Country Link
US (2) US6537793B2 (xx)
EP (1) EP1141249A1 (xx)
JP (1) JP2003523169A (xx)
KR (1) KR100762033B1 (xx)
CN (1) CN1195057C (xx)
AU (1) AU779267B2 (xx)
BR (1) BR9916654A (xx)
CA (1) CA2356373A1 (xx)
CZ (1) CZ20012428A3 (xx)
HU (1) HUP0104794A3 (xx)
IL (2) IL143381A0 (xx)
NO (1) NO20013271L (xx)
NZ (1) NZ512504A (xx)
PL (1) PL349074A1 (xx)
WO (1) WO2000040702A1 (xx)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ438398A3 (cs) * 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
EP1760151B1 (en) 1996-11-20 2012-03-21 Crucell Holland B.V. Adenovirus compositions obtainable by an improved production and purification method
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EA200001096A1 (ru) 1998-04-22 2001-04-23 Джинвек, Инк. Способ обогащения раствора аденовируса, способ точного подсчета числа аденовирусных частиц в образце раствора (варианты) и способ очистки аденовируса из клеток, инфицированных аденовирусом
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
IL143381A0 (en) * 1998-12-31 2002-04-21 Aventis Pharma Sa Method for separating viral particles
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
US20030224354A1 (en) * 2002-05-30 2003-12-04 Introgen Therapeutics Inc. Quantifying viral particles with intrinsic fluorescence
EP1371723A1 (en) * 2002-06-12 2003-12-17 Procorde GmbH Process for preparing an adenovirus-containing preparation
EP2281877A3 (en) 2003-05-21 2011-06-01 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
AU2004249199B2 (en) * 2003-06-18 2008-07-24 Onyx Pharmaceuticals, Inc. Method for purifying virus
EP1925626A1 (en) 2003-07-21 2008-05-28 Transgene S.A. Novel multifunctional cytokines
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
DE602005015332D1 (de) * 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
JP2008518632A (ja) 2004-11-03 2008-06-05 イントロゲン セラピューティックス， インコーポレイテッド アデノウイルスベクターの製造および精製のための新規方法
ES2317517T5 (es) * 2005-04-11 2016-01-21 Crucell Holland B.V. Purificación de virus usando ultrafiltración
ES2608638T3 (es) * 2005-07-06 2017-04-12 Ge Healthcare Bioprocess R&D Ab Método para preparar una matriz de separación
GB0515577D0 (en) * 2005-07-29 2005-09-07 Amersham Biosciences Ab Process for cross-linking cellulose ester membranes
EP1808697A1 (en) * 2006-01-13 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Use of an ion exchange matrix for determining the concentration of virus particles and/or virus antigens
KR100813268B1 (ko) * 2006-09-25 2008-03-13 삼성전자주식회사 이온교환반응 및 미생물 포획 수단을 이용하여 시료로부터미생물을 분리하는 방법, 미생물 시료의 전처리용 용기 및미생물분리 장치
EP2066418A4 (en) * 2006-09-29 2011-12-28 Ge Healthcare Bio Sciences Ab SEPARATION MATRIX FOR VIRAL PURIFICATION
ATE518958T1 (de) 2007-01-30 2011-08-15 Transgene Sa Zur impfung verwendetes papillomavirus-e2- polypeptid
EP2203481B1 (en) * 2007-05-04 2016-05-18 Bio-Works Technologies AB Method for the manufacture of agarose gels
DK2350268T3 (en) * 2008-11-03 2015-03-23 Crucell Holland Bv PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS
JP5716297B2 (ja) * 2009-06-25 2015-05-13 Jnc株式会社 クロマトグラフィー用充填剤、その製造方法、およびそれを用いたウイルス用ワクチンの製造方法
US9393299B2 (en) 2009-08-07 2016-07-19 Transgene S.A. Composition for treating HBV infection
JP5465331B2 (ja) * 2009-10-15 2014-04-09 クルセル ホランド ベー ヴェー 高細胞密度の培養物からのアデノウイルスの精製方法
US20130052165A1 (en) * 2010-01-12 2013-02-28 Livnat Bangio Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby
EA023816B1 (ru) 2010-02-15 2016-07-29 Круселл Холланд Б.В. СПОСОБ ПРОДУЦИРОВАНИЯ ВИРУСНЫХ ЧАСТИЦ Ad26
CN102985536B (zh) * 2010-04-14 2017-12-05 Emd密理博公司 生产高效价、高纯度的病毒母液的方法及使用其的方法
KR101847405B1 (ko) 2010-07-30 2018-04-10 이엠디 밀리포어 코포레이션 크로마토그래피 매질 및 방법
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
EP2649178B8 (en) 2010-12-09 2017-08-30 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
US11628381B2 (en) 2012-09-17 2023-04-18 W.R. Grace & Co. Conn. Chromatography media and devices
CN109134640A (zh) 2012-10-23 2019-01-04 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
JP6914189B2 (ja) 2014-05-02 2021-08-04 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 官能化担体材料並びに官能化担体材料を作製及び使用する方法
CN106794389A (zh) 2014-09-02 2017-05-31 Emd密理博公司 具有纳米原纤化表面特征的高表面积纤维介质
EP3230299A1 (en) 2014-12-08 2017-10-18 EMD Millipore Corporation Mixed bed ion exchange adsorber
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN107921407B (zh) 2015-06-05 2022-07-05 格雷斯公司 生物处理吸附澄清剂及其制备和使用方法
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
GB2573133A (en) 2018-04-25 2019-10-30 Ge Healthcare Bioprocess R&D Ab Separation matrix and method of separation
CN108949702A (zh) * 2018-08-01 2018-12-07 苏州纳微科技股份有限公司 超大孔径层析介质在纯化病毒颗粒的应用
GB201820806D0 (en) * 2018-12-20 2019-02-06 Ge Healthcare Bioprocess R&D Ab Large pore agarose
CN115326937B (zh) * 2021-05-11 2024-06-18 山东省食品药品检验研究院 一种基因毒杂质捕捉用固相探针及其使用方法与应用
GB202110014D0 (en) * 2021-07-12 2021-08-25 Cytiva Bioprocess R & D Ab A method for separating adeno-associated virus capsids, compositions obtained by said method and uses thereof
CN116768985B (zh) * 2022-12-07 2024-03-22 华北制药金坦生物技术股份有限公司 一种有效纯化病毒样颗粒的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595739A (en) * 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
CA2625279A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
CZ438398A3 (cs) * 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
EP1760151B1 (en) * 1996-11-20 2012-03-21 Crucell Holland B.V. Adenovirus compositions obtainable by an improved production and purification method
WO1998039467A2 (en) * 1997-03-03 1998-09-11 Calydon, Inc. Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
IL143381A0 (en) * 1998-12-31 2002-04-21 Aventis Pharma Sa Method for separating viral particles

Also Published As

Publication number Publication date
US20020037565A1 (en) 2002-03-28
CN1195057C (zh) 2005-03-30
CN1332796A (zh) 2002-01-23
KR20020044106A (ko) 2002-06-14
PL349074A1 (en) 2002-07-01
US6537793B2 (en) 2003-03-25
AU779267B2 (en) 2005-01-13
BR9916654A (pt) 2002-01-15
IL143381A (en) 2006-08-01
EP1141249A1 (fr) 2001-10-10
CZ20012428A3 (cs) 2001-11-14
HUP0104794A3 (en) 2006-03-28
WO2000040702A1 (fr) 2000-07-13
NZ512504A (en) 2004-01-30
HUP0104794A2 (hu) 2002-04-29
NO20013271D0 (no) 2001-06-29
KR100762033B1 (ko) 2007-10-04
US20030170710A1 (en) 2003-09-11
IL143381A0 (en) 2002-04-21
AU3049300A (en) 2000-07-24
JP2003523169A (ja) 2003-08-05
CA2356373A1 (fr) 2000-07-13

Similar Documents

Publication Publication Date Title
NO20013271L (no) Fremgangsmate for separering av virale partikler
DK0920631T3 (da) Fremgangsmåde til identifikation af forbindelser, som indvirker på interaktioner mellem RNA og RNA-bindende proteiner
AU1703500A (en) Method and apparatus for detecting viruses using primary and secondary biomarkers
DE69528418D1 (de) Betriebsart eines Ionenmobilitätsspektrometers zur verbesserten Detektion von Narcotica
DE69908832D1 (de) Übertragung von Daten zur Übung musikalischer Aufführungen
NO20042243L (no) Fremgangsmate og system for kodegjenbruk og kapasitetsforbedring ved bruk av nullstyring
DE69710177D1 (de) DVD-Platte, Vorrichtung und Methode zu ihrer Wiedergabe
GB2330655A (en) Method and system for performing a binding assay
AU1811197A (en) Method for treating biopolymers, microorganisms or materials by using more than one type of magnetic particles
AU2751199A (en) Method, apparatus and flow cell for high sensitivity detection of fluorescent molecules
BG104928A (en) Efficient purification of adenovirus
BR9702310A (pt) Estrutura fibrosa permeável de alto desempenho
IL139631A0 (en) Enumeration method of analyte detection
NO20032209D0 (no) Fremgangsmåte for separering og detektering av proteiner ved hjelp av elektroforese
DE69728139T2 (de) Pyrrolopyrrolone als inhibitoren von neutrophiler elastase
NO972022L (no) Fremgangsmåte ved fremstilling av papir
NO996511D0 (no) Fremgangsmåte, anordning og baerer ved koding av flerordsinformasjon
DK1528106T3 (da) Medium til detektion af målmikrober i en pröve
DK1242816T3 (da) Kromatografimateriale og fremgangsmåder ved anvendelse af dette
NO20005240L (no) Fremgangsmåte ved fremstilling av papir
FR2763342B1 (fr) Milieu de culture pour la detection specifique des enterobacteries, procede pour son obtention et son utilisation
FI990831A0 (fi) Menetelmä ja järjestelmä teollisuusprosessin suorituskyvyn analysoimiseksi
NO20001414D0 (no) Fremgangsmåte ved opprenskning av antitrombin III
GB9705646D0 (en) Principle identifying system, electronic settlement system, and recording medium to be used therefor
AU4282999A (en) Method of identifying antidepressant compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application